US2011280978A1PendingUtilityA1

Cosmetic use of botulinum toxin for the treatment of eyebrow and forehead ptosis, and unwanted eyebrow expression

34
Individually held — no corporate assignee on recordPriority: May 4, 2006Filed: Nov 10, 2010Published: Nov 17, 2011
Est. expiryMay 4, 2026(expired)· nominal 20-yr term from priority
Inventors:Kenneth D. Steinsapir
A61K 8/64C12Y 304/24069Y02A50/30A61Q 19/08A61K 38/4893
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to affect a more desirable appearance. In a broad aspect the invention comprises injecting small quantities of botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face. In sufficient numbers, injected microdroplets of BTX are able to selectively weaken these muscles. This method preferably also includes using microdroplets of BTX to treat: a) the depressor supercilii muscle, on each side; b) the procerus muscle; c) the corrugator supercilii muscle, on each side; and d) the inferior limit of the frontalis muscle where it meets the superior aspect of the orbital portion of the orbicularis oculi muscle.

Claims

exact text as granted — not AI-modified
1 . A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to effect a more desirable appearance, comprising:
 injecting small quantities of botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face, said microdroplets in large enough numbers being sufficient to selectively weaken these muscles.   
     
     
         2 . The method of  claim 1 , further including the step of injecting small quantities of BTX dissolved in microdroplets to treat the depressor supercilii muscle, on each side. 
     
     
         3 . The method of  claim 1 , further including the step of injecting small quantities of BTX dissolved in microdroplets to treat the procerus muscle. 
     
     
         4 . The method of  claim 1 , further including the step of injecting small quantities of BTX dissolved in microdroplets to treat the corrugator supercilii muscle, on each side. 
     
     
         5 . The method of  claim 1 , further including the step of injecting small quantities of BTX dissolved in microdroplets to treat the inferior limit of the frontalis muscle where it meets the superior aspect of the orbital portion of the orbicularis oculi muscle. 
     
     
         6 . The method of  claim 1 , further including the steps of injecting small quantities of BTX dissolved in microdroplets to treat: a) the depressor supercilii muscle, on each side; b) the procerus muscle; c) the corrugator supercilii muscle, on each side; and d) the inferior limit of the frontalis muscle where it meets the superior aspect of the orbital portion of the orbicularis oculi muscle. 
     
     
         7 . The method of  claim 1 , wherein said microdroplet injections are placed 0.5 to 1 millimeter below the skin surface to distribute the BTX between the skin and the underlying muscles to limit the diffusion of the BTX. 
     
     
         8 . The method of  claim 1 , wherein the BTX is locally administered using microdroplet volumes of BTX solution in amounts between about 0.01 milliliters and 0.05 milliliters. 
     
     
         9 . The method of  claim 1 , wherein the botulinum toxin (BTX) is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, and G as produced by the Clostridium botulinum bacterium. 
     
     
         10 . The method of  claim 1 , wherein the BTX is botulinum toxin A (BTX-A). 
     
     
         11 . The method of  claim 1 , wherein each microdroplet injected contains 0.001 to 1.0 Units of Botulinum toxin A adjusted based on the desired degree of muscle weakening. 
     
     
         12 . The method of  claim 1 , wherein the concentration of the BTX solution prepared for microdroplet administration is adjusted based on the relative strength of the BTX product used and the desired degree of muscle weakening. 
     
     
         13 . The method of  claim 1 , wherein each microdroplet contains 0.25 to 0.5 Units of BTX-A. 
     
     
         14 . The method of  claim 1 , wherein 30 to 90 microdroplet injections are distributed over the muscle groups to be treated. 
     
     
         15 . The method of  claim 1 , wherein the distribution of the microdroplet injections are adjusted to enhance brow shape and symmetry.

Join the waitlist — get patent alerts

Track US2011280978A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.